Kapoor Mohit, Kojima Fumiaki, Qian Min, Yang Lihua, Crofford Leslie J
Department of Internal Medicine, Rheumatology Division, University of Kentucky, Lexington, Kentucky 40536.
J Biol Chem. 2007 Feb 23;282(8):5356-66. doi: 10.1074/jbc.M610153200. Epub 2006 Dec 22.
mPGES-1 (microsomal PGE synthase-1) is an inducible enzyme that acts downstream of cyclooxygenase (COX) and specifically catalyzes the conversion of prostaglandin (PG) H(2) to PGE(2) under basal as well as inflammatory conditions. In this study, using mouse embryo fibroblasts (MEFs) isolated from mice genetically deficient for the mPges-1 gene, we show basal elevation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression (protein and mRNA) and transcriptional activity associated with reduced basal PGE(2). We further show that basal mPGES-1-derived PGE(2) suppresses the expression of PPARgamma through a cAMP-independent pathway involving phosphatidylinositol 3-kinase and Akt signaling. Using specific PPARgamma agonist (rosiglitazone), PPARgamma ligand (15-deoxy-Delta12,14-PGJ(2)), and PPARgamma inhibitor (GW9662), we confirm that activation of PPARgamma blocks interleukin-1beta-induced up-regulation of COX-2, mPGES-1, and their derived PGE(2). Furthermore, we demonstrate that up-regulation of PPARgamma upon genetic deletion of mPGES-1 is responsible for reduced COX-2 expression under basal as well as interleukin-1beta-stimulated conditions. This study provides evidence for the first time that mPGES-1 deletion not only decreases proinflammatory PGE(2) but also up-regulates anti-inflammatory PPARgamma, which has the ability to suppress COX-2 and mPGES-1 expression and PGE(2) production. Thus, mPGES-1 inhibition may limit inflammation by multiple mechanisms and is a potential therapeutic target.
微粒体前列腺素E合酶-1(mPGES-1)是一种诱导型酶,在环氧化酶(COX)下游起作用,在基础状态以及炎症状态下均能特异性催化前列腺素(PG)H2转化为PGE2。在本研究中,我们使用从小鼠胚胎成纤维细胞(MEF)中分离得到的mPges-1基因遗传缺陷小鼠,发现过氧化物酶体增殖物激活受体γ(PPARγ)表达(蛋白质和mRNA)的基础水平升高,且转录活性与基础PGE2水平降低相关。我们进一步表明,基础状态下由mPGES-1产生的PGE2通过涉及磷脂酰肌醇3激酶和Akt信号传导的非cAMP依赖性途径抑制PPARγ的表达。使用特异性PPARγ激动剂(罗格列酮)、PPARγ配体(15-脱氧-Δ12,14-PGJ2)和PPARγ抑制剂(GW9662),我们证实PPARγ的激活可阻断白细胞介素-1β诱导的COX-2、mPGES-1及其衍生的PGE2的上调。此外,我们证明,在mPGES-1基因缺失后PPARγ的上调导致在基础状态以及白细胞介素-1β刺激条件下COX-2表达降低。本研究首次提供证据表明,mPGES-1缺失不仅会降低促炎PGE2,还会上调具有抑制COX-2和mPGES-1表达及PGE2产生能力的抗炎性PPARγ。因此,mPGES-1抑制可能通过多种机制限制炎症,是一个潜在的治疗靶点。